

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>OCT 07 2003</u> (use as many sheets as necessary)		Application Number	10/714,593
		Filing Date	11/14/2003
Sheet <u>1</u> of <u>4</u>		First Named Inventor	Hua Xu
		Group Art Unit	1642
		Examiner Name	Fetterolf, Brandon J.
		Attorney Docket Number	056274-3451

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
							T <sup>6</sup>

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	1	AMY S. MORGAN, et al., "Tumor Efficacy and Bone Marrow-sparing Properties of TER286, a Cytotoxin Activated by Glutathione S-Transferase", Cancer Research 58: 2568-2575, June 15, 1998.		
	2	LILLIAM A. ROSARIO, et al., "Cellular Response to a Glutathione S-Transferase P1-1 Activated Prodrug", The American Society for Pharmacology and Experimental Therapies, Mol. Pharm. 58:167-174, 2000.		
	3	Telik press release, "Telik Announces Initiation of TLK286 Combination Chemotherapy Development Program", 2 pgs., October 7, 2002.		
	4A	Abstract #102 from Eur. J. Cancer, v. 38, supp. 7, which was made available at the 14 <sup>th</sup> EORTC-NCI-AACR Symposium, 3 pgs., November 19, 2002 (first day of symposium).		
	4B	Telik press release, "Telik Presents Preclinical Data Demonstrating Synergy of TLK286 in Combination with Multiple Approved Cancer Chemotherapy Drugs", 2 pgs., November 20, 2002.		
	4C	Poster (Keck, et al.) shown at the 14 <sup>th</sup> EORTC-NCI-AACR Symposium 1 pg., November 20, 2002.		
	5	Telik press release, "Telik Announces Initiation of Two Additional Clinical Trials of TLK286 in Combination Chemotherapy Regimes", 2 pgs., December 9, 2002.		
	6A	Abstract #1722 from Pro. Am. Assn. Cancer Res., V. 44, which was made available at the AACR Annual Meeting, 4 pgs., April 5, 2003, (first day of the meeting).		

Examiner Signature		Date Considered	11/16/03
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <i>(use as many sheets as necessary)</i>		Application Number	10/714,593
		Filing Date	11/14/2003
		First Named Inventor	Hua Xu
		Group Art Unit	1642
		Examiner Name	Fetterolf, Brandon J.
Sheet	2	of	2
		Attorney Docket Number	056274-3451


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
JP	6B	Poster (Xu, et al.) from Pro. Am. Assn. Cancer Res., which was shown at the AACR Annual Meeting, 1 pg., April 6, 2003.	
	6C	Telik press release, "Telik Announces New Preclinical Data on TLK286 That Supports Unique Mechanism of Activation, and Activity in Combinations With Standard Cancer Drugs", 2 pgs., April 9, 2003.	
	7A	Telik press release, "Telik Announces Positive Interim Results from Phase 1-2a Trial of Telcyta™ (TLK286) in Combination with Doxil®", 2 pgs., October 21, 2003.	
	7B	Telik press release, "Telik Announces Positive Interim Results from Phase 1-2a Trial of Telcyta™ (TLK286) in Combination with Docetaxel" 2 pgs., October 21, 2003.	
	7C	Telik press release, "Telik Announces Positive Interim Results from Phase 1-2a Trial of Telcyta™ (TLK286) in Combination with Carboplatin" 2 pgs., October 21, 2003.	
	7D	Telik press release, "Telik Announces Presentations at AACR-NCI-EORTC Conference", 2 pgs., November 13, 2003.	

Examiner Signature		Date Considered	2005/11/16
--------------------	---	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/714,593
				Filing Date	November 14, 2003
				First Named Inventor	XU, Hua et al.
				Group Art Unit	1645
Examiner Name	Unassigned				
Sheet	1	of	1	Attorney Docket Number	TLIK-049/01US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
bf	A1	5,556,942		Kauvar Lawrence M. et al	09-17-1996

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			
bf	B1	PCT	WO 96/40205		Terrapin Tech Inc.	12-19-1996	

OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
bf	C1	Anonymous: "Two secondary offerings hopeful?", SCRIP, No. 2790, 16 October 2002 (2002-10-16), page 12 XP009028508	
	C2	Abstract, DATABASE PHARMAPROJECTS Online, PJB Publications Ltd, United Kingdom, Database accession no. 10581, XP002278756 No date	
	C3	Abstract "Enhanced antitumor activity of TLK286 in combination with carboplatin, doxorubicin and docetaxel in human ovarian and breast cancer cell lines", European Journal Of Cancer, Pergamon Press, Oxford, GB, vol. 38, November 2002 (2002-11), page S35, XP004403542, ISSN: 0959-8049	
bf	C4	Kauvar LM et al., "Glutathione Based Approaches To Improving Cancer Treatment", Chemico-Biological Interactions, Elsevier, Science Ireland, IR, vol. 111/112, 1998, pages 225-238, XP000938463, ISSN: 0009-2797	

Examiner Signature	<i>Bush K. Allen</i>	Date Considered	11/16/03
-----------------------	----------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.